rsRolesWithAccess DOES NOT exist
InDevEnvironment=false
rsRolesWithAccess numRows = [0]
IsInternalUser=[false]
InDevEnvironment=[false]
IsSectionSecure=[false]
Authorized=[false]
LMSAccess=[false]
HasNeuroHCP=[false]
UserLoggedIn=[false]

MRI with DBS

Indications and Safety Information

See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events.

Consult instructions for use at manuals.medtronic.com. Manuals can be viewed using a current version of any major Internet browser. For best results, use Adobe® Reader with the browser. 

Medtronic DBS Therapy for Movement Disorders

Medtronic DBS Therapy for Movement Disorders is indicated for patients with disabling tremor or symptoms of Parkinson's disease. Studies have shown that deep brain stimulation with Medtronic DBS Therapy components is effective in controlling essential tremor and symptoms of Parkinson's disease that are not adequately controlled with medications. Additionally, deep brain stimulation is effective in controlling dyskinesias and fluctuations associated with medical therapy for Parkinson's disease.

Medtronic DBS Therapy for Movement Disorders is also indicated as an aid in the management of chronic, intractable (drug refractory) primary dystonia, including generalized and segmental dystonia, hemidystonia, and cervical dystonia (torticollis) for individuals 7 years of age and older.

Clinicians, refer to the appropriate information for prescribers booklet for contraindications, warnings, precautions, adverse events summary, patient selection, and component disposal.

Patients, refer to your Medtronic DBS patient therapy guide for contraindications, warnings, precautions, and other risk information.


Medtronic DBS Therapy for Epilepsy

Bilateral anterior thalamic nucleus (ANT) stimulation using the Medtronic DBS System for Epilepsy is indicated as adjunctive therapy for reducing the frequency of seizures in adults diagnosed with epilepsy characterized by partial-onset seizures, with or without secondary generalization, that are refractory to antiepileptic medications.1

Refer to the appropriate information for prescribers booklet for contraindications, warnings, precautions, adverse events summary, individualization of treatment, patient selection, use in specific populations, resterilization, and component disposal.


DBS Therapy for Obsessive-Compulsive Disorder

Medtronic Reclaim® DBS Therapy is indicated for bilateral stimulation of the anterior limb of the internal capsule, AIC, as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive-compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs).

These components comprise the implantable portion of the Reclaim DBS System for bilateral OCD therapy.

  • Soletra® Model 7426 or Kinetra® Model 7428 Neurostimulator
  • Activa® PC Model 37601, Activa SC Model 37602, or Activa SC Model 37603 Neurostimulator
  • Model 7482, Model 7482A, Model 7483, Model 37085, or Model 37086 Extension
  • Model 3391 Lead

Refer to the appropriate information for prescribers booklet for contraindications, warnings, precautions, adverse events summary, individualization of treatment, patient selection, use in specific populations, resterilization, and component disposal.

Clinicians, refer to the appropriate information for prescribers booklet for contraindications, warnings, precautions, adverse events summary, individualization of treatment, patient selection, use in specific populations, resterilization, and component disposal.

Patients, refer to your Medtronic DBS Patient Therapy guide for contraindications, warnings, precautions, and other risk information.


Reference
  1. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2009;1-9. doi: 10.1111/j.1528-1167.2009.02397.x.

 

Europe